Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: A retrospective, multicenter analysis

Background and aims: Body composition parameters and immunonutritional indexes provide useful information on the nutritional and inflammatory status of patients. We sought to investigate whether they predict the postoperative outcome in patients with pancreatic cancer (PC) who received neoadjuvant therapy (NAT) and then pancreaticoduodenectomy. Methods: Data from locally advanced PC patients who underwent NAT followed by pancreaticoduodenectomy between January 2012 and December 2019 in four high-volume institutions were collected retrospectively. Only patients with two available CT scans (before and after NAT) and immunonutritional indexes (before surgery) available were included. Body composition was assessed and immunonutritional indexes collected were: VAT, SAT, SMI, SMA, PLR, NLR, LMR, and PNI. The postoperative outcomes evaluated were overall morbidity (any complication occurring), major complications (Clavien-Dindo ≥ 3), and length of stay. Results: One hundred twenty-one patients met the inclusion criteria and constituted the study population. The median age at the diagnosis was 64 years (IQR16), and the median BMI was 24 kg/m2 (IQR 4.1). The median time between the two CT-scan examined was 188 days (IQR 48). Skeletal muscle index (SMI) decreased after NAT, with a median delta of −7.8 cm2/m2 (p < 0.05). Major complications occurred more frequently in patients with a lower pre-NAT SMI (p = 0.035) and in those who gained in subcutaneous adipose tissue (SAT) compartment during NAT (p = 0.043). Patients with a gain in SMI experienced fewer major postoperative complications (p = 0.002). The presence of Low muscle mass after NAT was associated with a longer hospital stay [Beta 5.1, 95%CI (1.5, 8.7), p = 0.006]. An increase in SMI from 35 to 40 cm2/m2 was a protective factor with respect to overall postoperative complications [OR 0.43, 95% (CI 0.21, 0.86), p < 0.001]. None of the immunonutritional indexes investigated predicted the postoperative outcome. Conclusion: Body composition changes during NAT are associated with surgical outcome in PC patients who receive pancreaticoduodenectomy after NAT. An increase in SMI during NAT should be favored to ameliorate the postoperative outcome. Immunonutritional indexes did not show to be capable of predicting the surgical outcome

Fitting Early Phases of the COVID-19 Outbreak: A Comparison of the Performances of Used Models

The COVID-19 outbreak involved a spread of prediction efforts, especially in the early pandemic phase. A better understanding of the epidemiological implications of the different models seems crucial for tailoring prevention policies. This study aims to explore the concordance and discrepancies in outbreak prediction produced by models implemented and used in the first wave of the epidemic. To evaluate the performance of the model, an analysis was carried out on Italian pandemic data from February 24, 2020. The epidemic models were fitted to data collected at 20, 30, 40, 50, 60, 70, 80, 90, and 98 days (the entire time series). At each time step, we made predictions until May 31, 2020. The Mean Absolute Error (MAE) and the Mean Absolute Percentage Error (MAPE) were calculated. The GAM model is the most suitable parameterization for predicting the number of new cases; exponential or Poisson models help predict the cumulative number of cases. When the goal is to predict the epidemic peak, GAM, ARIMA, or Bayesian models are preferable. However, the prediction of the pandemic peak could be made carefully during the early stages of the epidemic because the forecast is affected by high uncertainty and may very likely produce the wrong results

Surveillance of Individuals at High Risk of Developing Pancreatic Cancer:A Prevalence Meta-analysis to Estimate the Rate of Low-yield Surgery

Objective: To quantify the rate of low-yield surgery, defined as no high-grade dysplastic precursor lesions or T1N0M0 pancreatic cancer at pathology, during pancreatic cancer surveillance. Background: Global efforts have been made in pancreatic cancer surveillance to anticipate the diagnosis of pancreatic cancer at an early stage and improve survival in high-risk individuals (HRIs) with a hereditary predisposition. The negative impact of pancreatic cancer surveillance when surgery is performed for low-grade dysplasia or a non-neoplastic condition is not well quantified. Materials and Methods: A systematic search and prevalence meta-analysis was performed for studies reporting surgery with final diagnoses other than those defined by the Cancer of the Pancreas Screening (CAPS) goals from January 2000 to July 2023. The secondary outcome was the pooled proportion of final diagnoses matching the CAPS goals (PROSPERO: CRD42022300408). Results: Twenty-three articles with 5027 patients (median 109 patients/study, interquartile range 251) were included. The pooled prevalence of low-yield surgery was 2.1% (95% CI: 0.9-3.7, I 2: 83%). In the subgroup analysis, this prevalence was nonsignificantly higher in studies that only included familial pancreatic cancer subjects without known pathogenic variants, compared with those enrolling pathogenic variant carriers. No effect modifiers were found. Overall, the pooled prevalence of subjects under surveillance who had a pancreatic resection that contained target lesions was 0.8% (95% CI, 0.3-1.5, I 2: 24%]. The temporal analysis showed that the rate of low-yield surgeries decreased in the last decades and stabilized at around 1% (test for subgroup differences P&lt;0.01). Conclusions: The risk of "low-yield" surgery during pancreatic cancer surveillance is relatively low but should be thoroughly discussed with individuals under surveillance.</p

Surveillance of Individuals at High Risk of Developing Pancreatic Cancer: A Prevalence meta-analysis to Estimate the Rate of low-yield Surgery

Objective: To quantify the rate of low-yield surgery, defined as no high-grade dysplastic precursor lesions or T1N0M0 pancreatic cancer at pathology, during pancreatic cancer surveillance. Summary background data: Global efforts have been made in pancreatic cancer surveillance to anticipate the diagnosis of pancreatic cancer at an early stage and improve survival in high-risk individuals (HRI) with a hereditary predisposition. The negative impact of pancreatic cancer surveillance when surgery is performed for low-grade dysplasia or a non-neoplastic condition is not well-quantified. Methods: A systematic search and prevalence meta-analysis was performed for studies reporting surgery with final diagnoses other than those defined by the CAPS goals from January 2000 to July 2023. The secondary outcome was the pooled proportion of final diagnoses matching the CAPS goals (PROSPERO: #CRD42022300408). Results: Twenty-three articles with 5,027 patients (median 109 patients/study, IQR 251) were included. The pooled prevalence of low-yield surgery was 2.1% [95%CI 0.9-3.7], I2 83%). In the subgroup analysis, this prevalence was non-significantly higher in studies that only included familial pancreatic cancer (FPC) subjects without known pathogenic variants (PV), compared to those enrolling PV carriers. No effect modifiers were found. Overall, the pooled prevalence of subjects under surveillance who had a pancreatic resection that contained target lesions was 0.8% [95%CI 0.3-1.5], I2 24%). The temporal analysis showed that the rate of low-yield surgeries decreased in the last decades and stabilized at around 1% (test for subgroup differences P&lt;0.01). Conclusions: The risk of "low-yield" surgery during pancreatic cancer surveillance is relatively low but should be thoroughly discussed with individuals under surveillance

Surveillance of Individuals at High Risk of Developing Pancreatic Cancer:A Prevalence Meta-analysis to Estimate the Rate of Low-yield Surgery

Objective: To quantify the rate of low-yield surgery, defined as no high-grade dysplastic precursor lesions or T1N0M0 pancreatic cancer at pathology, during pancreatic cancer surveillance. Background: Global efforts have been made in pancreatic cancer surveillance to anticipate the diagnosis of pancreatic cancer at an early stage and improve survival in high-risk individuals (HRIs) with a hereditary predisposition. The negative impact of pancreatic cancer surveillance when surgery is performed for low-grade dysplasia or a non-neoplastic condition is not well quantified. Materials and Methods: A systematic search and prevalence meta-analysis was performed for studies reporting surgery with final diagnoses other than those defined by the Cancer of the Pancreas Screening (CAPS) goals from January 2000 to July 2023. The secondary outcome was the pooled proportion of final diagnoses matching the CAPS goals (PROSPERO: CRD42022300408). Results: Twenty-three articles with 5027 patients (median 109 patients/study, interquartile range 251) were included. The pooled prevalence of low-yield surgery was 2.1% (95% CI: 0.9-3.7, I 2: 83%). In the subgroup analysis, this prevalence was nonsignificantly higher in studies that only included familial pancreatic cancer subjects without known pathogenic variants, compared with those enrolling pathogenic variant carriers. No effect modifiers were found. Overall, the pooled prevalence of subjects under surveillance who had a pancreatic resection that contained target lesions was 0.8% (95% CI, 0.3-1.5, I 2: 24%]. The temporal analysis showed that the rate of low-yield surgeries decreased in the last decades and stabilized at around 1% (test for subgroup differences P&lt;0.01). Conclusions: The risk of "low-yield" surgery during pancreatic cancer surveillance is relatively low but should be thoroughly discussed with individuals under surveillance.</p

Voce: Prelievi e analisi di campioni

Con la legge 30.6.2009 n. 85 l'Italia ha ratificato l'adesione al Trattato di Pr\ufcm, in vista del rafforzamento della cooperazione tra Stati nella lotta al terrorismo, alla criminalit\ue0 transfrontaliera e alla migrazione illegale, tramite lo scambio di informazioni genetiche. La novit\ue0 pi\uf9 saliente che l'adesione al Trattato ha importato nell'ordinamento interno concerne l'introduzione di un'inedita disciplina dei prelievi coattivi di materiale biologico, volta alla tutela dei diritti individuali nell'impiego processuale di strumenti tecnico-scientifici che consentano di non disperdere il materiale probatorio relativo ad un fatto criminoso. Il tema rievoca la tradizionale distinzione che attribuisce all'imputato la duplice funzione di \u201corgano\u201d ed \u201coggetto\u201d nella formazione della prova, a seconda del contributo attivo o passivo che lo stesso apporti alla vicenda processuale. Questi \ue8 considerato \u201corgano\u201d di prova nell'espletamento di attivit\ue0 che costituiscono esercizio del diritto di difesa, nelle due componenti, positiva e negativa, del diritto di difendersi provando e del diritto al silenzio. Viceversa, si parla di imputato come \u201coggetto\u201d di prova allorquando gli sia richiesto un mero pati rispetto all'attivit\ue0 di istruzione probatoria, come accade nelle ispezioni, nelle perquisizioni, nelle ricognizioni personali, nonch\ue9, pi\uf9 in generale, negli accertamenti che si espletano sul corpo del giudicabile, il quale viene in rilievo non come parte processuale, ma come mera entit\ue0 fisica. Il regime di nuovo conio \ue8 intervenuto a colmare la lacuna normativa lasciata dalla sentenza n. 238 del 1996 con cui la Corte costituzionale aveva dichiarato l'illegittimit\ue0 dell'art. 224, comma 2, c.p.p. nella parte in cui consentiva interventi peritali sul corpo della persona, in violazione del principio di riserva di legge che presidia, ex art. 13 Cost., la libert\ue0 personale. La pronuncia ha individuato un \u201cnocciolo duro\u201d rappresentato dalla libert\ue0 corporale, indissolubilmente legata ai principi di libert\ue0 morale, integrit\ue0 psico-fisica e salute della persona, non comprimibili a fini processuali. La Carta fondamentale prevede un'unica ipotesi di lesione del diritto alla salute nell'ambito dei trattamenti sanitari obbligatori, per finalit\ue0 estranee all'accertamento penale; la libert\ue0 morale, peraltro, rappresenta il quid pluris che sopravvive alla compressione del potere statale, persino durante la pi\uf9 intensa restrizione della libert\ue0 personale. Se questo \ue8 il quadro costituzionale di riferimento, \ue8 evidente come il previgente regime in materia di prelievi biologici coattivi abbia disatteso le indicazioni provenienti dalla Consulta. Difatti, a distanza di quasi un decennio dal monito del Giudice delle leggi, il legislatore intervenne (con la legge 31 luglio 2005, n. 155) \uabin un modo persino pi\uf9 imbarazzante dell'inerzia sino ad allora mantenuta\ubb, attribuendo un potere di intrusione corporale (attraverso il prelievo di capelli o saliva nel corso delle indagini) alla polizia giudiziaria, previa autorizzazione - anche orale, purch\ue9 confermata per iscritto - del pubblico ministero, a soli fini identificativi e purch\ue9 sussistesse il pericolo di alterazione o dispersione della res. Non era contemplato il potere giudiziale di disporre un prelievo biologico a fini peritali e l\u2019esclusivo orientamento teleologico dell\u2019atto d\u2019indagine ne limitava fortemente l\u2019utilit\ue0. Veniva, pertanto, inopinatamente elusa la doppia riserva, di legge e di giurisdizione, che presidia la materia. La riforma realizza una netta soluzione di continuit\ue0 rispetto alla normativa precedente, attraverso l'individuazione nell'organo giurisdizionale del baricentro del micro-sistema normativo dedicato ai prelievi biologici coattivi. Se la libert\ue0 personale pu\uf2 subire restrizioni per atto motivato dell'autorit\ue0 giudiziaria, pertanto anche del pubblico ministero, l'intrusione nella sfera corporale esige l'egida di un soggetto super partes, indifferente rispetto all'esito del processo. Il legislatore ha costruito una disciplina minuziosa, concernente sia l'an che il quomodo dei prelievi, in ossequio alla riserva di legge dettagliata (nei \u201cmodi\u201d e nei \u201ccasi\u201d) imposta dalla Consulta. Ne \ue8 derivato un apparato \uabmulti-livello\ubb, calibrato sulla sistematica del codice e diversificato in base all'orientamento teleologico dell'accertamento \u2013istituzionale, probatorio, investigativo o identificativo-, in cui ogni tipologia \ue8 rigidamente separata dalle altre